Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Escalation Study of TAS-115 in Advanced Solid Tumors
jRCT2080221605Phase 1
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pamufetinib in Nonhematologic neoplasms, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of TAS-115 and Pharmacokinetics of TAS-115.
02
Drugs
pamufetinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221605.